Who are Idarubicin(IDA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ADM, idarubicin, etoposide, cytarbine, teniposide, Daunorubicin/Idarubicin, Epirubicin (E), Epirubicin Injectable Product, Doxorubicin (A).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/idarubicin-ida.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Idarubicin(IDA) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Idarubicin(IDA) (Idarubicin(IDA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline topoisomerase II inhibitor. Area: Oncology.

marketed Anthracycline topoisomerase II inhibitor Topoisomerase II; DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Idarubicin(IDA) (Idarubicin(IDA)) — Chinese Academy of Medical Sciences. Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Idarubicin(IDA) TARGET	Idarubicin(IDA)	Chinese Academy of Medical Sciences	marketed	Anthracycline topoisomerase II inhibitor	Topoisomerase II; DNA
ADM	ADM	Italian Sarcoma Group	marketed	Anthracycline chemotherapy agent	Topoisomerase II; DNA
idarubicin, etoposide, cytarbine, teniposide	idarubicin, etoposide, cytarbine, teniposide	St. Jude Children's Research Hospital	phase 3	Combination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog)	Topoisomerase II; DNA synthesis
Daunorubicin/Idarubicin	Daunorubicin/Idarubicin	Institute of Hematology & Blood Diseases Hospital, China	phase 3	Anthracycline chemotherapy agent	Topoisomerase II; DNA
Epirubicin (E)	Epirubicin (E)	Eye & ENT Hospital of Fudan University	marketed	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA
Epirubicin Injectable Product	Epirubicin Injectable Product	The First Affiliated Hospital with Nanjing Medical University	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA
Doxorubicin (A)	Doxorubicin (A)	Merck Sharp & Dohme LLC	phase 3	Anthracycline topoisomerase II inhibitor	Topoisomerase II, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthracycline topoisomerase II inhibitor class)

Asan Medical Center · 1 drug in this class
Chinese Academy of Medical Sciences · 1 drug in this class
Eye & ENT Hospital of Fudan University · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Stichting Hemato-Oncologie voor Volwassenen Nederland · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Idarubicin(IDA) — Competitive Intelligence Brief. https://druglandscape.com/ci/idarubicin-ida. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing